Craig-Hallum analyst Alexander Nowak made no change to the firm’s Buy rating and $117 price target on Natera and its Hold rating and $8 price target on CareDx after Medicare contractor Novitas said Thursday that its coverage determination for oncology tests L39365 will not be going into effect. The firm considers whether this move creates precedent for CareDx and Natera to rebuke MolDx.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CDNA: